Abstract:Background: Glioma is the most lethal and most aggressive brain cancer, and currently there is no effective treatment. Cancer immunotherapy is an advanced therapy by manipulating immune cells to attack cancer cells and it has been studied a lot in glioma treatment. Targeting the immune checkpoint CD47 or blocking the CD47-SIRPα axis can effectively eliminate glioma cancer cells but also brings side effects such as anemia. Glutaminyl-peptide cyclotransferase-like protein (QPCTL) catalyzes the pyroglutamylation of CD47 and is crucial for the binding between CD47 and SIRPα. Further study found that loss of intracellular QPCTL limits chemokine function and reshapes myeloid infiltration to augment tumor immunity. However, the role of QPCTL in glioma and the relationship between its expression and clinical outcomes remains unclear. Deciphering the role of QPCTL in glioma will provide a promising therapy for glioma cancer immunotherapy. Methods: QPCTL expression in glioma tissues and normal adjacent tissues was primarily analyzed in The Cancer Genome Atlas (TCGA) database, and further validated in another independent cohort from the Gene Expression Omnibus (GEO) database, Chinese Glioma Genome Atlas (CGGA), and Human Protein Atlas (HPA). The relationships between QPCTL expression and clinicopathologic parameters and overall survival (OS) were assessed using multivariate methods and Kaplan-Meier survival curves. And the proteins network with which QPCTL interacted was built using the online STRING website. Meanwhile, we use Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA) databases to investigate the relationships between QPCTL expression and infiltrated immune cells and their corresponding gene marker sets. We analyzed the Differentially Expressed Genes (DEGs) including GO/KEGG and Gene Set Enrichment Analysis (GSEA) based on QPCTL-high and -low expression tumors. Results: In contrast to normal tissue, QPCTL expression was higher in glioma tumor tissue ( p < 0.05). Higher QPCTL expression was closely associated with high-grade malignancy and advanced tumor stage. Univariate and multivariate analysis indicated the overall survival of glioma patients with higher QPCTL expression is shorter than those with lower QPCTL expression ( p < 0.05). Glioma with QPCTL deficiency presented the paucity of infiltrated immune cells and their matching marker sets. Moreover, QPCTL is essential for glioma cell proliferation and tumor growth and is a positive correlation with glioma cell stemness. Conclusion: High QPCTL expression predicts high grades of gliomas and poor prognosis with impaired infiltration of adaptive immune cells in the tumor microenvironment as well as higher cancer stemness. Moreover, targeting QPCTL will be a promising immunotherapy in glioma cancer treatment.

CPVL promotes glioma progression via STAT1 pathway inhibition through interactions with the BTK/p300 axis

PVT1 promotes proliferation and macrophage immunosuppressive polarization through STAT1 and CX3CL1 regulation in glioblastoma multiforme

Long non-coding RNA PVT1 indicates a poor prognosis of glioma and promotes cell proliferation and invasion via target EZH2.

PVT1 Regulates the Malignant Behaviors of Human Glioma Cells by Targeting Mir-190A-5p and Mir-488-3p.

YTHDC1-mediated VPS25 regulates cell cycle by targeting JAK-STAT signaling in human glioma cells

The role of SPI1/VSIG4/THBS1 on glioblastoma progression through modulation of the PI3K/AKT pathway

Up-regulation of LPCAT1 is correlated with poor prognosis and promotes tumor progression in glioblastoma

Lowly Expressed Lncrna PVT1 Suppresses Proliferation and Advances Apoptosis of Glioma Cells Through Up-Regulating Microrna-128-1-5p and Inhibiting PTBP1

Deciphering the role of QPCTL in glioma progression and cancer immunotherapy

PVT1 affects growth of glioma microvascular endothelial cells by negatively regulating miR-186.

LncRNA-PVT1 Indicates a Poor Prognosis and Promotes Angiogenesis Via Activating the HNF1B/EMT Axis in Glioma

RTVP-1 promotes mesenchymal transformation of glioma via a STAT-3/IL-6-dependent positive feedback loop

Valosin-containing Protein Regulates the Proteasome-Mediated Degradation of DNA-PKcs in Glioma Cells.

A novel peptide P1-121aa encoded by STK24P1 regulates vasculogenic mimicry via ELF2 phosphorylation in glioblastoma

ITPKA phosphorylates PYCR1 and promotes the progression of glioma

Integrated analysis reveals CP is a potential biomarker and therapeutic target in glioma

PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2

Protein Phosphatase 1γ Regulates the Proliferation of Human Glioma Via the NF-κB Pathway

Significant Role of PPP3CB in Malignant Gliomas Development, Prognosis and Potential Therapeutic Application—a Study Based on Comprehensive Bioinformatics, Cell Experiments and Immunohistochemistry Analyses

Long Noncoding RNA PVT1 Promotes Stemness and Temozolomide Resistance Through Mir-365/Elf4/sox2 Axis in Glioma.

SVIP reduces IGFBP-2 expression and inhibits glioblastoma progression via stabilizing PTEN